Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 22

  • 741 clinical trials
  • 263 recruiting
  • 237 conditions
  • 26 countries

Conditions in this area

237 conditions with trials, the busiest first

Obesity116Type 2 diabetes mellitus83Overweight51Type 1 diabetes mellitus38Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis22Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Dyslipidaemia8Iron deficiency8Phenylketonuria8+213

Clinical trials in Metabolism and nutrition disorders

741 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

741 clinical trials

Alpha-1 antitrypsin deficiency

Recruiting

Study on Long-Term Safety of Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Type 2 diabetes mellitus

Recruiting

Study on Sodium Phenylbutyrate for Improving Blood Sugar Control in Type 2 Diabetes Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Phenylbutyrate
  • Sponsor:Universiteit Maastricht

Osteoporosis

Recruiting

Study on the Use of Romosozumab and Zoledronic Acid for Treating Osteoporosis in Patients

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Romosozumab
  • Sponsor:Region Midtjylland

Hyperglycaemia+1

Recruiting

Study on the Safety and Effectiveness of Oral Semaglutide for Patients with High Blood Sugar After Kidney Transplantation

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Region Hovedstaden

Type 2 diabetes mellitus

Recruiting

Comparison of dapagliflozin and oral semaglutide effectiveness in type 2 diabetes patients based on insulin resistance or secretion deficit

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Hypoglycaemia

Recruiting

Study on Sotagliflozin for Treating Low Blood Sugar After Weight Loss Surgery in Patients with Post-Bariatric Hypoglycemia

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Steno Diabetes Center Copenhagen

Glycogen storage disease type II

Recruiting

Study on the Safety and Efficacy of Avalglucosidase Alfa for Patients Aged 5 and Older with Non-Classic Pompe Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Avalglucosidase Alfa
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Metabolic disorder

Recruiting

Study on Semaglutide for Weight Control in Patients with Schizophrenia and High BMI Using Antipsychotics

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Helse Bergen HF

Oedema peripheral

Recruiting

Study on the Effect of Dexamethasone and Betamethasone Sodium Phosphate on Leg Swelling in Patients Undergoing Total Hip Replacement

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Betamethasone Sodium Phosphate
  • Sponsor:Hospital Universitari De Girona Doctor Josep Trueta

Malabsorption

Recruiting

Study on the Effects of ELGN-2112 (Human Insulin) for Treating Intestinal Malabsorption in Preterm Infants

Investigational
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Insulin Human
  • Sponsor:Elgan Pharma Ltd.

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

Study of Namodenoson Treatment in Patients with Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Namodenoson
  • Sponsor:Can-Fite Biopharma Ltd.

Pituitary-dependent Cushing's syndrome

Not yet recruiting

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ATUMELNANT
  • Sponsor:Crinetics Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide76 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsTirzepatide13 clinical trialsParacetamol12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.